Therapeutic drug monitoring for immune mediated inflammatory diseases

Editorial

Open access

Peer reviewed

Neil Chanchlani, Zenas Z N Yiu, Lisa K Stamp and Andrew S Day

BMJ medicine, Vol.3(1), e001130

10/2024

Handle:

https://hdl.handle.net/10523/43142

Abstract

drug monitoring

immune mediated inflammatory diseases

Infliximab

adalimumab

biologics

Low certainty evidence suggests a proactive approach during maintenance therapy for patients treated with infliximab.

pdf

e001130.full196.72 kBDownload View

Published (Version of record)CC BY-NC V4.0, Open Access

url

https://doi.org/10.1136/bmjmed-2024-001130View

Published (Version of record) Open

18 File views/ downloads

12 Record Views

Record Identifier: 9926616418101891
Title: Therapeutic drug monitoring for immune mediated inflammatory diseases
Creators: Neil Chanchlani
Zenas Z N Yiu
Lisa K Stamp
Andrew S Day
Publication Details: BMJ medicine, Vol.3(1), e001130
Academic Unit: Medicine (UOC); Paediatrics and Child Health (UOC)
Publisher: BMJ Group
Date published ; e-published: 10/2024
Copyright: Copyright © 2024 The Author(s). This work was first published in BMJ Medicine (BMJ). This is an Open Access article distributed under the terms of the Creative Commons‐Attribution‐NonCommercial License 4.0 International (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial use, reproduction, adaptation and distribution of the work in any medium provided the original work is properly attributed to the creator(s) and the source, a link to the Creative Commons license is provided, and any changes made are indicated.
Language: English
Resource Type ; Subtype: Editorial